Indian biopharmaceuticals company Biocon’s Malaysian subsidiary has secured a MYR300m ($67.6m) contract from the Ministry of Health (MoH), Malaysia, for the supply of recombinant human insulin (rh-Insulin) formulations.

Under the three-year contract, Biocon will supply rh-Insulin cartridges and re-usable insulin pens.

The contract can also be extended for another two years, subject to approval by the Government of Malaysia.

Biocon chairperson and managing director Kiran Mazumdar-Shaw said: “We are pleased to support the Ministry of Health of Malaysia in providing high-quality, affordable, rh-insulin for people with diabetes in Malaysia.

“It is a matter of pride that this is a ‘Made in Malaysia’ insulin product manufactured by Biocon at the BioXcell Biotech Park in Nusajaya, Johor.”

The company will supply insulin that is manufactured at its 800,000ft² biopharmaceutical facility in Johor, Malaysia, which was established with an investment of MYR1.1bn ($247.9m)

"We are pleased to support the Ministry of Health of Malaysia in providing high-quality, affordable, rh-insulin for people with diabetes in Malaysia."

Biocon’s rh-Insulin biosimilar biologic product has been approved by Malaysia’s National Pharmaceutical Regulatory Authority (NPRA) for commercial sales in the country.

The company will distribute the formulations through CCM Pharmaceuticals, which serves primary healthcare clinics and hospitals across the region.

The contract will be serviced under the Malaysian government’s off-take agreement (OTA) initiative, which is aimed at encouraging local manufacturing of new pharmaceutical products and reducing the country’s reliance on imports.

The company has received regulatory approvals for rh-Insulin in more than 60 emerging markets and is currently providing the product in these markets through its local partners.

Biocon’s integrated insulins facility at the Bio-Xcell biotech park in Iskandar was selected as an entry point project (Epp) under Malaysia’s Healthcare National Key Economic Area (NKEA) initiative.